Objectives: To study the results on survival of radical cystectomy and pelvic lymphadenectomy in bladder cancer with pelvic node metastases in a retrospective study. Patients and Methods: Of 248 patients with transitional cell carcinoma of the bladder treated by cystectomy with pelvic lymphadenectomy from 1970 to 1990,40 (16%; 37 males, 3 females) had pelvic nodal metastases. Fifteen patients had one positive lymph node (stage pN1) and 25 patients had more than one positive node (stage pN2). Preoperative pelvic radiotherapy was realized in 14 patients. Results: The perioperative mortality rate was 5% and the perioperative morbidity rate 15%. The overall 1- and 5-year survival rates for patients with nodal metastases were, respectively, 42 and 14%. Overall median survival was 9 months (range: 1-288 months). Three patients are still alive with follow-ups of 7, 12 and over 20 years. Kaplan-Meier survival curves revealed no survival advantage for stage pN1 over pN2 disease (p = 0.10). The 5-year survival rate for patients with stage pN1 was 22% with a median of survival of 17 months (range: 1–288 months). The 5-year survival rate for patients with pN2 disease was 8% with a median of survival of 7 months (range: 1-144 months). The cause of the death was tumoral progression in 26 patients (75%) and local recurrence in 3 patients (10%). A preoperative radiotherapy didn’t influence survival. Conclusion: In our experience, radical cystectomy with pelvic lymphadenectomy provided long-term progression-free survival for a few patients with nodal involvement. Efficacious adjuvant therapy has to be found to improve the results.

Keywords:
Bladder carcinoma, Lymph nodes, Metastases, Radical cystectomy
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.